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Depending on their mechanism of action, anticonvulsant drugs in clinical use may be divided into three 
groups: those drugs which facilitate ~-aminobutryic a id (GABA)ergic neurotransmission; those which block 
neuronal ion channels; and those whose mechanism of action is unresolved. The compounds acting on GABAer- 
gic systems may be further subdivided into those which modulate transmission through chloride channels, e.g. 
the barbiturates and the benzodiazepines; those compounds, in particular vigabatrin, which reduce the degra- 
dation of GABA by blocking GABA transaminase; and those which inhibit the re-uptake of GABA into the 
presynaptic terminal. 
The other group of compounds whose mechanism of action is known are those which block neuronal ion 
channels. Blockage of voltage-operated sodium channels by lamotrigine, phenytoin or carbamazepine leads to 
decreased electrical activity and, probably, asubsequent reduction in glutamate release. Conversely, ethosuxi- 
mide, blocks voltage-operated calcium channels, especially those which mediate calcium currents in thalamic 
neurones. 
Of those drugs in which the mechanism of action is unknown, sodium valproate is the prime example. An 
antagonistic action at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor might also be a 
possibility, which could be the case with some of the newer compounds currently undergoing evaluation. 
Key words: epilepsy; anticonvulsants; mechanisms ofaction. 
INTRODUCTION 
In spite of a considerable research effort, the 
neurochemical irregularities underlying epi- 
lepsy are still not clearly understood. Un- 
controlled electrical activity in the central 
nervous system may occur, either through a 
reduction in inhibitory neurotransmission r, 
conversely, through an increase in excitatory 
transmission. Changes in ionic conductances 
through neuronal membranes may underlie 
these abnormalities. 
The major groupings of antiepileptic drugs 
can be defined as: 
1. those which facilitate ~/-aminobutyric acid 
(GABA) transmission by various mechan- 
isms; 
2. those which block voltage-gated ion channels 
and thus reduce excitatory transmission; 
3. those whose mechanism of action is still open 
to debate. 
DRUGS ACTING ON GABAERGIC 
MECHANISMS 
GABA is the major inhibitory transmitter 
throughout the neuroaxis and functions as the 
transmitter in both long axonal tracts and, 
perhaps more importantly in relation to epi- 
lepsy, is the transmitter of many interneurones. 
The function of these cells is to regulate the 
electrical activity in relatively small areas of 
neuropile and consequently the output of that 
area. For example, the vast majority of inter- 
neurones in the cerebral cortex are GABAergic 
and play an important part in controlling luta- 
mate-mediated excitatory activity within the 
cortex, as well as excitatory output from the 
cortex. There are two subtypes of GABA recep- 
tors, designated GABAA and GABAB. GABAA 
receptors (which are bicuculline-sensitive) are 
located predominantly on postsynaptic mem- 
branes and are involved in fast neurotrans- 
mission; it is the interaction with these 
receptors that accounts for the action of both the 
benzodiazepines and the barbiturates. 
The GABAA receptor is part of the trans- 
mitter-gated channel which consists of five 
membrane-spanning subunits that form the 
pore through which chloride ions enter the 
postsynaptic neurone following GABAA recep- 
tor occupation. Each of the five subunits in 
turn consists of four distinct transmembrane- 
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spanning domains. These subunits, which form 
the ionophore, have been designated ~, ~, ~, 8 
and p, and each, with the exception of 8, have 
multiple isoforms. As a result of amino acid 
sequencing, there are six ~ subunits (al-a6), 
four 13 subunits (~1-~4), three ~ subunits (~- 
~3), a single ~ subunit, as well as two p sub- 
units (pl-p2), with the latter appearing to be 
localized in the retina (see Enna for a review) 1. 
The presence of these many isoforms, and 
consequently of different pentameric ombi- 
nations of subunits, raises the possibility of 
many different types of GABAA receptors with 
varying physiological characteristics. At 
present it is known, following co-expression f
the various ubunits in Xenopus oocytes, that 
and 13 subunits must be combined with a ~2 or 
~3 in order to obtain a normal response to 
benzodiazepines, while substitution with a 
subunit removes any sensitivity. 
The action of the benzodiazepines is described 
as allosteric modulation, because these drugs 
have no intrinsic activity at the GABAA recep- 
tor, both drug and transmitter having to be 
present simultaneously in order to facilitate 
neurotransmission. The resulting effect is an 
increased frequency ofopening of chloride chan- 
nels. In the case of phenobarbitone there is a 
prolongation i  the open time of the channel. 
The resulting influx of chloride leads to hyper- 
polarization of the postsynaptic neurone and 
consequently a decrease inneuronal firing rate. 
It must also be pointed out that a 2,3-benzo- 
diazepine molecule (GYKI 52466), which has 
anticonvulsant properties, has been shown to 
non-competitively block the AMPA (L-alpha- 
amino-3-hydroxy-5-methyl-4-isoxazole-propri- 
onic acid)/kainate subtype of glutamate recep- 
tor2; phenobarbitone has also been reported to 
be an antagonist at this receptor 3. 
The mechanism of action of vigabatrin is 
also through a modification of GABAergic 
transmission. Following the release of GABA 
from a presynaptic terminal, some 70-80% of 
the transmitter is taken back into the neurone 
by a specific sodium/chloride voltage- 
dependent re-uptake system. However, some of 
the released GABA is metabolized to succinic 
semialdehyde byGABA-transaminase and this 
also occurs to a small proportion of the GABA 
which is taken up into the terminal. Viga- 
batrin, by blocking GABA-transaminase 4, in- 
creases both synaptic and terminal GABA 
levels, thus leading to a potentiation of 
GABAergic-induced inhibition. 
A further group of drugs with the potential 
to facilitate GABAergic transmission is that 
which inhibits the re-uptake of GABA. The 
prototypic ompound in this group was nipe- 
cotic acid which was shown to be an effective 
re-uptake inhibitor in vitro. However, when 
given in vivo it did not cross the blood-brain 
barrier. Currently undergoing clinical trials, a 
derivative of nipecotic acid, tiagabine, has 
been shown to block the re-uptake of GABA 5 
and to be active in vivo. 
GABAB receptors, which are bicuculline 
insensitive, are found both pre- and post- 
synaptically and are linked to guanosine tri- 
phosphate (GTP) binding proteins. Depending 
on the cellular location of these receptors, acti- 
vation can lead to various physiological effects. 
GABAB receptors (autoreceptors) located on 
presynaptic GABAergic terminals are involved 
in the regulation of GABA release 6. Stimu- 
lation of these receptors leads to a decrease in 
GABA release, either through the opening of 
potassium channels or by inhibiting calcium 
entry into the terminal. Either (or both) mech- 
anisms would lead to a reduction in exocytosis. 
Antagonists at GABAB autoreceptors would 
have potential anticonvulsant activity. 
DRUGS ACTING ON VOLTAGE-OPERATED 
ION CHANNELS 
Voltage-operated sodium and calcium ion 
channels in neuronal membranes are modified 
by antiepileptic drugs in current clinical 
usage. An inhibitory action at either, or both, 
of these channels has a marked effect of 
neuronal activity. 
The anticonvulsant action of phenytoin is 
considered to be via a membrane-potential- 
dependent blockade of sodium channels. 
However, such a general reduction in sodium- 
mediated transmission in a tetrodotoxin 
(TTX)-like manner is difficult o reconcile with 
a selective action of the drug on seizures. 
Phenytoin is far more effective in reducing 
sodium currents during high-frequency repeti- 
tive stimulation (neuronal conditions which 
are present during a seizure) than during 
normal brain activity which occurs at lower 
frequencies 7. The diversity of voltage-operated 
potassium and calcium channels has been 
recognized for a number of years. However, it 
is only recently that different voltage-operated 
sodium channels have been described (see 
Mandel for a review) s. These channels have 
been shown to have varying pharmacological 
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and functional characteristics. Perhaps the 
most important functional difference in these 
channels is their inactivation kinetics in that 
some which are sensitive to TTX are slowly 
inactivating and these may thus play a vital 
role in sustained firing, as seen during a seiz- 
ure. A specific action of phenytoin on a subtype 
of sodium channel could account for its phar- 
macological ction. 
Phenytoin has also been shown to affect 
extacellular Ca 2+ concentration by blocking 
the potassium-stimulated uptake of Ca 2+ into 
brain slices 9. During a seizure l°, or even before 
the initiation of a seizure 1~, the extracellular 
concentration of potassium increases mark- 
edly, resulting in depolarization of the 
neurones in that region. This depolarization 
leads to a decrease in extracellular calcium 
concentration as voltage-operated calcium 
channels open and calcium goes down its con- 
centration gradient into the neurone. The in- 
creased interneuronal calcium concentration 
would then lead to exocytosis and enhanced 
excitatory neurotransmission; phenytoin, by 
blocking the entry of calcium, would reduce 
this excitation. However, an action of pheny- 
toin on sodium channels could also account for 
these changes in the extracellular concen- 
trations of calcium and potassium. 
Lamotrigine ~2 and carbamazepine 13 have 
both been shown to have similar actions to 
phenytoin i  that they are able to decrease sus- 
tained repetitive high-frequency stimulation of 
neuronal preparations. This action of both 
compounds may again be explained by an 
effect on voltage-operated sodium channels. 
Lamotrigine has also been shown to decrease 
the release of veratridine-stimulated gluta- 
mate from rat cortical slices, but was without 
effect on potassium-stimulated release 14. 
These results with lamotrigine again point to 
an action on voltage-operated so ium channels 
in that veratridine opens these channels. The 
reduction in the release of the major excitatory 
neurotransmitter in the central nervous 
system might account for the anticonvulsant 
action of lamotrigine, but it does appear con- 
tradictory in that TTX also blocks veratridine- 
induced glutamate r lease ~5, but obviously has 
no anticonvulsant properties. 
Carbamazepine, as well as being an anticon- 
vulsant, is used in bipolar illness and in the 
treatment of trigeminal neuralgia. As stated 
above, this drug also blocks sustained repeti- 
tive firing through an inhibitory action on 
sodium channels 13 and also facilitates potass- 
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ium efflux. Either of these mechanisms could 
account for its antiepileptic action. However, 
two recent papers have shown that carbamaze- 
pine blocks the N-methyl-D-aspartate (NMDA) 
subtype of glutamate receptor in cultured 
spinal cord neurones 16and in cortical wedges 
prepared from genetically epilepsy-prone DBA/ 
2 mice 17. In this latter study, concentrations of 
0,5--10ftM carbamazepine reduced NMDA- 
evoked depolarizations but concentrations 
above 50pM potentiated the depolarizations. 
This inhibitory action of carbamazepine on 
NMDA receptors could contribute to its anti- 
convulsant action (see later). 
The final drug in this group of antagonists at
voltage-operated ionchannels i ethosuximide. 
It is well documented that ethosuximide 
reduces low-threshold calcium currents (T- 
current) in thalamic preparations at thera- 
peutic concentrations18. Thalamocortical 
neurones have been shown to have a spon- 
taneous oscillatory activity of low frequency 
(approximately 3 Hz) and these pacemaker os- 
cillations involve T-currents. These oscillatory 
currents are considered to play an important 
role in the generation of 3Hz spike-wave 
rhythms characteristic of absence epilepsy. 
The action of ethosuximide in reducing these 
T-currents probably explains its therapeutic 
action. Recent evidence on the role of GABAB 
receptors in the thalamus have shown that ac- 
tivation of these receptors produces hyper- 
polarization which promotes T-currents and 
enhances seizure frequency in animal models, 
while GABAB receptor antagonists decreased 
the incidence of seizures ~9. These results might 
explain why absence seizures are aggravated 
by those drugs which facilitate GABAergic 
neurotransmission. 
DRUGS WHOSE MECHANISM OF ACTION IS 
UNRESOLVED 
Although sodium valproate has been in clinical 
use for the treatment of a wide spectrum of 
seizure types for many years, its mechanism of
action is still not fully understood. Early work 
suggested that valproate increased GABA 
levels presynaptically rather than acting 
through a facilitatory action on postsynaptic 
receptor mechanisms. The elevation of GABA 
concentrations could be accounted for by val- 
proate inhibiting the enzymes involved in 
GABA degradation (GABA transaminase and 
succinic semialdehyde); however, concen- 
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trations needed for such an action are much 
higher than those achieved clinically 2° and 
valproate is far less effective in this respect 
than is vigabatrin. Valproate has also been 
shown to increase GABA synthesis through 
stimulation of glutamic acid decarboxylase. 
Valproate also decreases the effect of high- 
frequency repetitive firing of sodum-dependent 
action potentials in a use- and voltage- 
dependent manner. Howver, 2-en-valproate, a 
metabolite of valproate, which has equivalent 
anticonvulsant properties to the parent com- 
pound in some animal models of epilsepy, has 
no effect on high-frequency repetitive firing of 
sodium-dependent action potentials 23. This 
latter observation raises doubts about the 
blockage of the sodium channel hypothesis. 
Another possible mechanism of action, es- 
pecially as valproate is effective in absence 
seizures, is an inhibition of low-threshold T- 
currents, as is the case with ethosuximide. 
However, Coulter et al is found no effect on this 
current in thalamic neurones, whereas Kelly et 
a121 reported that valproate reduced T-current 
in nodose ganglion neurones. Sodium val- 
proate has also been shown to activate a pot- 
assium conductance in rat hippocampal s ices 
and such an action would lead to an efflux of 
potassium and subsequent hyperpolariz- 
ation 22. It is probable that the reason why 
valproate has such a wide spectrum of anticon- 
vulsant activity is due to a combination of 
mechanisms ofaction, its effect on GABAergic 
systems being augmented by possible sodium 
and T-current channel blockade (see Loscher 
for a recent review23). 
Gabapentin, which has recently been intro- 
duced, has been shown to be effective in partial 
and generalized epilepsy. It was originally syn- 
thesized as a lipophilic analogue of GABA 
which would cross the blood-brain barrier. 
However, gabapentin does not possess high af- 
finity for either GABAA or GABAB receptors. 
Initial studies uggested an antagonistic effect 
at the glycine modulatory site on the NMDA 
receptor complex (see below) in that D-serine 
(an agonist at this site) reversed the anticon- 
vulsant action of gabapentin on tonic seizures 
in mice. However, binding studies demon- 
strated that gabapentin did not displace [3H] 
glycine or [3H]MK801 binding to brain mem- 
branes. A recent paper 24 compared the distri- 
bution of NMDA and gabapentin binding sites 
and showed that, while qualitatively there was 
close similarity between the two sites, quanti- 
tatively there were marked ifferences. Gaba- 
pentin has also been shown to bind to a novel 
high-affinity site in the central nervous ystem 
and to be displaced by the anticonvulsant 3- 
isobutyl GABA. There is evidence that this site 
may be linked to the transporter for large 
neutral L-amino acids such as L-methionine, L- 
leucine and L-isoleucine. These amino acids 
also potently displace gabapentin from its 
binding site 25. The significance of this finding 
and its possible relationship to an anticonvul- 
sant action is unknown. In addition, recent 
work has shown that gabapentin does not have 
any effect on sodium or calcium voltage- 
dependent channels or on GABA, glycine or 
glutamate (both NMDA and non-NMDA) 
receptors 26. 
NMDA receptors play an important role in 
the mechanisms underlying epilepsy. The 
NMDA receptor-operated complex consists of 
an ion channel that allows an influx of calcium 
and to a lesser extent sodium and an efflux of 
potassium..As well as the channel, there are a 
number of binding sites on this complex where 
antagonism could have potential anticonvul- 
sant properties. 
Felbamate has been shown to have anticon- 
vulsant properties against NMDA-induced 
convulsions in mice and also to inhibit binding 
of [3H] 5,7 dichloro:kynurenic acid at the gly- 
cine site on the NMDA receptor 27. The glycine 
site positively modulates NMDA receptor acti- 
vation and antagonists at this site show anti- 
convulsant properties. Such an action could 
account for the anticonvulsant effects of felba- 
mate. 
Another compound undergoing clinical trials 
is remacemide whose activity probably resides 
in its desglycine metabolite. Remacemide is ef- 
fective in inhibiting the effects of maximal 
electroshock in rats and NMDA-induced seiz- 
ures in mice. In binding studies 2s the parent 
compound was reported not to bind to gluta- 
mate, GABAA, adenosine A1, benzodiazepine 
or NMDA receptors (at either the glycine or ion 
channel sites). However, further work showed 
that the desglycinated metabolite displaced 
MK801 binding from rat synaptosomal mem- 
branes. An antagonistic action of remacemide 
desglycine at a site(s) on the NMDA receptor- 
operated channel is probable. 
In conclusion, the mechanism ofaction of the 
long-established anticonvulsant drugs on post- 
synaptic GABA receptors (benzodiazepines and 
phenobarbit0ne), or through inl~ibitory actions 
on voltage-sensitive ion cha~nels (voltage- 
operated sodium channels for pl~enytoin, lamo- 
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trigine, and carbamazepine; voltage-operated 
calcium channels for ethosuximide) are well 
defined. The mode of action of sodium val- 
proate is still open to debate, but it might well 
be that it has many actions which all contrib- 
ute in some way to its wide spectrum of anti- 
convulsant activity. Much further work is 
needed to define the mechanisms of action of 
gabapentin, felbamate and remacemide. 
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